Abstract: (a) R.sub.1 and R.sub.5 are hydrogen and R.sub.3 is n-propyl, isobutyl, cyclopentylmethyl, benzyl or 2-(p-fluorophenyl)ethyl;(b) R.sub.1 is fluorine and R.sub.5 is hydrogen and R.sub.3 is n-propyl;(c) R.sub.1 is methyl and R.sub.5 is hydrogen and R.sub.3 is cyclopropylmethyl;(d) R.sub.1 is cyano and R.sub.5 is hydrogen and R.sub.3 is n-propyl;(e) R.sub.1 is hydrogen, R.sub.5 is methyl and R.sub.3 is alkyl of 2 to 5 carbon atoms, cycloalkylmethyl of 5 to 7 carbon atoms in the cycloalkyl part thereof or --(CH.sub.2).sub.n --R' wherein n is 0, 1 or 2 and R' is phenyl or monofluorophenyl; or(B) R is hydroxy, R.sub.1 is fluorine and R.sub.5 is hydrogen, and their physiologically hydrolysable derivatives, in which at least one hydroxy group is in esterifiedform, and their salts, elicit highly cardioselective beta 1 adrenoceptor blockade, and in most cases cardiospecific blockade, and relevant cardiotonic activity. These compounds can be used as therapeutic agents.

Abstract: Compounds of formula (I), ##STR1## characterized in that R signifies optionally substituted heteroaryl-, heteroarylakyl or heteroarylalkenyl, R.sub.1 signifies hydrogen or a substituent, R.sub.2 is hydroxy or a group --z--(CH.sub.2).sub.n --Y--R.sub.3 wherein R.sub.3 is hydrogen, alkyl, hydroxyalkyl, alkenyl, cycloalkyl, cycloalkylalkylene, hydroxy substituted cycloalkyl or cycloalkylalkylene, or optionally substituted aryl or aralkyl or aralkenyl moiety, and Y signifies oxygen or sulfur, and either Z is an oxygen atom and n is 2 or 3, or Z is a bond and n is 1, 2 or 3, A signifies alkylene or branched alkylene of 2 to 5 carbon atoms, W signifies a bond or imino, and X signifies a bond or imino, and their physiologically hydrolyzable derivatives, in which at least one hydroxy group is in esterified form. The compounds exhibit beta adrenoceptor blocking activity. Processes for the preparation of the compounds are also disclosed.

Abstract: The compounds of formula I, ##STR1## where the substituents have various significances, and physiologically acceptable hydrolyzable derivatives thereof having the hydroxy group in the 2 position of the 3-aminopropoxy side chain in esterified form, are useful as cardioselective .beta.-adrenoceptor blocking agents.

Abstract: The compounds of formula I, ##STR1## where the substituents have various significances, and physiologically acceptable hydrolyzable derivatives thereof having the hydroxy group in the 2 position of the 3-aminopropoxy side chain in esterifield form, are useful as cardioselective .beta.-adrenoceptor blocking agents.

Abstract: The compounds of formula I, ##STR1## wherein the substituents have various significances, and physiologically hydrolyzable derivative thereof having at least one hydroxy group in esterified form, are useful as cardioselective .beta.-adrenoceptor blocking and cardiotonic agents.

Abstract: An optically active or racemic 2-amino-5-hydroxy-1,2,3,4-tetrahydronaphthalene wherein the nitrogen atom of the amino group carrier two alkyl groups, one of which is unsubstituted and the other is substituted by at least one functional group, or a physiologically hydrolysable ester thereof in free base form or in the form of an acid addition salt thereof is provided which is active against heart circulatory disorders and Morbus Parkinson and inhibits prolactin secretion inhibition.

Abstract: The invention concerns novel compounds of the formula: ##STR1## wherein n is 1, 2 or 3 R.sub.1 is lower alkylR.sub.2 is hydrogen or lower alkyl andA is a tricyclic moiety,Useful as sedative-neuroleptic, muscle-relaxant and sleep-promoting agents.